Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.22, sa.2, ss.242-247, 2016 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 22 Sayı: 2
- Basım Tarihi: 2016
- Doi Numarası: 10.1177/1078155214567162
- Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.242-247
- Anahtar Kelimeler: Trastuzumab, breast cancer, cardiotoxicity, onco-pharmacology, risk factors, ADJUVANT TRASTUZUMAB, CARDIAC DYSFUNCTION, THERAPY, DOXORUBICIN
- Çukurova Üniversitesi Adresli: Evet
Özet
Background: Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic.